Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marisa Iborra

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Biomedicines|March 25, 2022
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease SeverityLuis G Guijarro, David Cano-Martínez, M Val Toledo-Lobo, et al.
Inflammatory Bowel Diseases|March 3, 2016
Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort StudyIván Guerra, Tamara Pérez-Jeldres, Marisa Iborra, et al.
European Journal of Gastroenterology & Hepatology|April 7, 2020
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's diseaseMaría Chaparro, Iván Guerra, Marisa Iborra, et al.
Therapeutic Advances in Gastroenterology|October 11, 2019
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's diseaseMaría Chaparro, Adrià Aterido, Iván Guerra, et al.
Revista Espanola De Enfermedades Digestivas|September 29, 2025
Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remissionBeatriz Gros, Noemí Manceñido, José Manuel Benítez, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 10, 2022
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registryMíriam Mañosa, Agnès Fernández-Clotet, Pilar Nos, et al.
Alimentary Pharmacology & Therapeutics|May 3, 2025
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCUMaría José Casanova, Cristina Rubín de Célix, Sabino Riestra, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 3, 2021
Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involvedLuis G Guijarro, David Cano-Martínez, M Val Toledo-Lobo, et al.
The American Journal of Gastroenterology|January 31, 2025
HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA RegistryMargalida Calafat, Carles Suria, Francisco Mesonero, et al.
The American Journal of Gastroenterology|July 15, 2024
HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registryMargalida Calafat, Carles Suria, Francisco Mesonero, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Biomedicines|March 25, 2022
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease SeverityLuis G Guijarro, David Cano-Martínez, M Val Toledo-Lobo, et al.
Inflammatory Bowel Diseases|March 3, 2016
Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort StudyIván Guerra, Tamara Pérez-Jeldres, Marisa Iborra, et al.
European Journal of Gastroenterology & Hepatology|April 7, 2020
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's diseaseMaría Chaparro, Iván Guerra, Marisa Iborra, et al.
Therapeutic Advances in Gastroenterology|October 11, 2019
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's diseaseMaría Chaparro, Adrià Aterido, Iván Guerra, et al.
Revista Espanola De Enfermedades Digestivas|September 29, 2025
Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remissionBeatriz Gros, Noemí Manceñido, José Manuel Benítez, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 10, 2022
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registryMíriam Mañosa, Agnès Fernández-Clotet, Pilar Nos, et al.
Alimentary Pharmacology & Therapeutics|May 3, 2025
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCUMaría José Casanova, Cristina Rubín de Célix, Sabino Riestra, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 3, 2021
Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involvedLuis G Guijarro, David Cano-Martínez, M Val Toledo-Lobo, et al.
The American Journal of Gastroenterology|January 31, 2025
HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA RegistryMargalida Calafat, Carles Suria, Francisco Mesonero, et al.
The American Journal of Gastroenterology|July 15, 2024
HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registryMargalida Calafat, Carles Suria, Francisco Mesonero, et al.
Pageof 10